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To the Editor:
The latest guidelines suggest considering home treatment or early hospital discharge in low-risk mortality
pulmonary embolism (PE) patients, identified through widely validated clinical prediction rules [1, 2].
Nevertheless, it is still not clear if these patients are really treated on an outpatient basis in clinical
practice.
Thus, we used the RIETE registry (ClinicalTrials.gov identifier: NCT02832245) to assess the proportion of
outpatients with acute PE initially treated in-hospital, the mean duration of hospitalisation and to identify
predictors for home treatment or for early discharge. We included data from 11473 patients registered in
25 countries participating in the RIETE study from January 2010 to December 2016. Both local and
academic hospitals were involved. Rate and duration of hospitalisation for acute PE in the four countries
with highest enrolment and in other participating countries, grouped together as a unique group, were
compared. Namely, patients enrolled in Spain (n=8270) were compared with those included in France
(n=964), Italy (n=593), Israel (n=429) and in “other countries” (n=1217).
All the variables potentially associated with outpatient treatment and with early discharge (length of
in-hospital stay (LOS) ⩽5 days) were evaluated at the univariate analysis using the Mann–Whitney test
(for continuous variables) and the Chi-squared or Fisher’s exact tests (for dichotomous variables).
Statistically or marginally significant variables (p<0.10) were introduced in a multivariate model (backward
binary logistic regression model). The role of different scores, such as the Pulmonary Embolism Severity
Index (PESI) [3], the RIETE score [4] and the scheme suggested by the American College of Chest
Physicians guidelines (ACCP scheme) for the bleeding risk [2], was assessed performing three different
sensitivity analyses, excluding all the variables already included in each score. SPSS software (version 15;
SPSS Inc., Chicago, IL, USA) was used for statistical analysis. A two-sided p-value of 0.01 was considered
to be statistically significant.
A significantly lower proportion of complete outpatient treatment was found among PE subjects treated in
Spain (2.5%), France (1.2%) and Israel (0.99%) than among those treated in Italy and the other countries
(16% and 21%, respectively, p<0.001 for both). By contrast, the number of patients discharged within
5 days was significantly lower in Italy (23%), Spain (26%) and France (28%) than in Israel and the other
countries examined (48% and 32%, respectively, p<0.001 for both). The mean LOS was substantially
shorter in Israel (median (interquartile range) 6 (4–9) days, p<0.001) than in other countries. Only 5% of
the overall population and ∼7% of the low-risk group were fully treated at home. The median duration of
hospitalisation was 4 days for patients discharged early and 9 days for those with a longer hospitalisation.
On multivariate analysis, initial therapy with direct oral anticoagulants (DOACs) and cancer strongly
predicted both home treatment and early discharge. Admission to university hospitals was significantly
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associated with home treatment and showed a tendency towards a shorter hospital stay. Use of oestrogenic
therapy was solely a predictor of early discharge.
When scores were entered one by one in the model, results concerning all previous variables were
comparable except for the weight of a number of comorbidities and initial presentation parameters (data
not shown). Low PESI or low ACCP scores were not associated with home treatment, both resulting
uniquely as weak predictors of a shorter LOS. Low RIETE score weakly predicted both home treatment
and early discharge (table 1).
Considering this real-life data collected from several countries, overall, only one in every 13 patients
eligible for home treatment was treated at home and less than half of the low-risk population was
hospitalised for ⩽5 days.
These results are not surprising since, until now, the level of evidence on outpatient treatment remains
limited by the lack of high-quality research [5]. The variable approaches observed among countries may
reflect different healthcare systems and facilities across European and world countries. Various scores,
classifying dissimilar low-risk patients, were tested in our cohort, but none of them appeared clearly
related to outpatient treatment. It remains to be verified if, in the near future, further validations of well
performing clinical prediction rules, such as the Hestia clinical criteria, may help to increase the rate of
TABLE 1 Multivariate analysis using complete home treatment and early discharge as the dependent variable#
Variables (number of patients) Home versus in hospital therapy
OR (CI)
Early discharge (⩽5 days) or home
treatment versus admission >5 days
OR (CI)
Clinical characteristics
Age >65 years 0.59 (0.46–0.76)*** 0.77 (0.69–0.86)***
Male sex (n=5413) 1.19 (1.08–1.32)***
Body weight <75 kg 1.12 (1.02–1.24)*
Initial presentation
Pulse >110 beats per min (n=2214) 0.33 (0.23–0.48)*** 0.62 (0.55–0.71)***
Systolic BP levels <100 mmHg (n=888) 0.50 (0.26–0.93)*
Temperature <36°C (n=756) 0.82 (0.68–0.99)*
Risk factors
Cancer (n=2550) 2.55 (2.00–3.27)*** 1.30 (1.16–1.45)***
Immobility ⩾4 days (n=1663) 0.82 (0.71–0.95)**
Oestrogen therapy (n=630) 1.68 (1.37–2.07)***
Underlying conditions
Chronic heart failure (n=931) 0.74 (0.61–0.89)**
Chronic lung disease (n=1598) 0.80 (0.70–0.92)**
Creatinine clearance levels <60 mL·min−1 (n=3963) 0.81 (0.72–0.91)***
Countries
Spain (n=8270) Ref.*** Ref.***
Italy (n=593) 5.17 (3.11–8.58)***
France (n=964) 0.48 (0.25–0.90)*
Israel (n=429) 0.36 (0.13–0.97)* 2.12 (1.68–2.67)***
Other countries (n=1217) 11.50 (9.02–14.66)*** 2.25 (1.93–2.62)***
Initial therapy
LMWH (n=9935) Ref.*** Ref.***
Unfractionated heparin (n=647) 0.16 (0.07–0.35)*** 0.36 (0.28–0.46)***
Thrombolytics (n=328) 0.35 (0.24–0.50)***
DOACs (n=196) 5.26 (3.36–8.24)*** 2.92 (2.08–4.09)***
Fondaparinux (n=297) 0.41 (0.25–0.67)***
Type of hospital
University hospital (n=7025) 2.29 (1.74–3.01)*** 1.11 (1.01–1.23)*
Scores
PESI <85 points (n=4792) 1.20 (0.98–1.47) 1.33 (1.21–1.46)***
RIETE <1 point (n=3347) 1.29 (1.04–1.60)* 1.57 (1.42–1.74)***
ACCP scheme ⩽1 point (n=1759)¶ 1.29 (0.98–1.69) 1.46 (1.28–1.66)***
BP: blood pressure; LMWH: low-molecular-weight heparin; Ref.: reference; DOACs: direct oral anticoagulants; PESI: Pulmonary Embolism
Severity Index; ACCP: American College of Chest Physicians. #: patients dying ⩽24 h after the index event were excluded from this analysis;
¶: modified version (information on control of anticoagulation was unavailable in the RIETE registry). Scores included one by one excluding all
the variables already counted in each score. *: p<0.05; **: p<0.01; ***: p<0.001.
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outpatient-treated patients in real-life settings, reducing barriers concerning this practice [6]. The ongoing
HOME-PE trial might clarify if a strategy based on the Hestia rule, compared with a strategy based on the
simplified-PESI score, is at least as safe with regards to the 30-day rate of adverse events and more
effective with regards to the rate of patients eligible for outpatient treatment [7].
Interestingly, in our study, cancer patients were more frequently treated at home or promptly discharged
despite evident higher haemorrhagic and thrombotic risk [8]. Notably, incidentally detected asymptomatic
cancer-related PE were not included in the population analysed. Commonly, cancer patients may be
monitored by oncologists with close follow-up visits and such well-defined assistance programmes may
facilitate either an outpatient strategy or a post-discharge management. At the same time, this category of
patients may achieve more benefits from home treatment, since a new hospitalisation usually deteriorates
their quality of life [9].
As expected, initial treatment with DOACs appeared correlated with outpatient treatment and a shorter
LOS. At the time of data collection, only 196 patients in the initial phase of therapy and 996 in the
long-term period were treated with DOACs. These drugs, especially those permitting the “single drug
approach”, may broadly facilitate a quick discharge from emergency wards after a comprehensive risk
assessment of PE patients [10–13]. The ongoing Mercury-PE trial, designed to test the hypothesis that
management with rivaroxaban, if compared with standard care, reduces the number of initial and
subsequent hospitalisation days of low-risk PE, will probably confirm these findings [14]. However, in this
observational analysis we are not able to exclude that, in daily clinical practice, DOACs were mainly
preferred in the acute phase of treatment for less complex subgroups of patients.
Finally, additional considerations should be taken into account. Up until the end of 2013, the previous
guidelines only suggested early discharge for low-risk PE [15] and use of DOACs was not allowed in most
countries. From 2014, for the first time, the European Society of Cardiology guidelines suggested both use
of DOACs and home treatment for low-risk PE patients [1]. In analysing data from 2010 to 2016, we are
probably observing a period of great change with regards to managing PE. Our results relating to academic
institutions may suggest that, in these centres, guideline recommendations could potentially be
implemented more easily and quickly than in other institutions since a paradigm shift requires more time
to be adopted in all clinical settings.
Our study has some limitations. Principally, RIETE is an ongoing observational registry. Therefore, our
findings should be treated with caution considering the limitations of observational studies. Moreover, the
data collected from multiple centres in different countries participating in the RIETE registry may not be
representative of the general treatment in those countries and only patients evaluated in a specific setting
may be included. Thus, our data can not be fully generalisable nor used as proof for implementing our
results into daily clinical practice.
In the near future, diagnostic and therapeutic advances may be able to optimise low-risk PE patient
selection and at the same time improve the management of this disease, providing an approach as safe as
and more cost-effective than the current one.
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